Mylan's generic Copaxone wins in court, but market barriers remain

The U.S. Court of Appeals for the Federal Circuit last week found Teva's Copaxone 40 mg/mL dosing patents to be "invalid as obvious," supporting previous rulings made by the U.S. District Court for the District of Delaware and the Patent Trial and Appeal Board.